PhaseV, the developer of advanced AI/machine learning (ML) solutions to optimize clinical development, has entered into a strategic partnership with Bioforum to increase clinical trial efficiency through advanced AI/ML technology.
This collaboration brings PaseV's Trial Optimizer platform to integrated into Bioforum's existing biometric services.
Discover the B2B marketing to run
Combining business intelligence with editorial excellence, it reaches enthusiastic experts from 36 leading media platforms.
Please see more
The purpose of the integration is to streamline the path from protocol planning to execution using AI-powered solutions.
This approach is designed to assist research sponsors in the design, simulation, and optimization of complex tests with the potential to accelerate timelines, reduce costs and improve success rates, while maintaining scientific and regulatory standards.
The trial optimizer platform uses AI/ML to quickly simulate and compare numerous trial configurations, allowing sponsors to select the most effective design before patient enrollment begins.
By incorporating this technology into Bioforum's services, the partnership seeks to eliminate expensive handoffs between the design and delivery teams and minimize the risk of protocol modifications. This integration is expected to speed up the decision-making process in a variety of therapeutic areas.
Bioforum is known for its expertise in biometric authentication and data quality commitment and offers a range of services including data management, biostatistics, statistical programming, and medical documentation.
The inclusion of the PhaseV platform improves the bioforum's ability to support efficient and high-quality clinical research. The platform will allow faster iteration, improve statistical reliability, reduce operational friction, and allow sponsors to conduct optimized testing without additional transition costs.
Recent obesity studies using a trial optimizer platform have been able to reduce the required sample size by approximately 20% while maintaining statistical power.
Raviv Pryluk, co-founder and CEO of PhaseV, said:
“This partnership will provide our trial sponsors with the ability to simulate millions of scenarios and seamlessly move from design to execution without losing time.”
In February 2025, PhaseV partnered with Alimentiv to support the design and execution of indication trials focusing on gastrointestinal conditions.
